Production and biomedical applications of virus-like particles derived from polyomaviruses

EA Teunissen, M de Raad, E Mastrobattista - Journal of Controlled Release, 2013 - Elsevier
Abstract Virus-like particles (VLPs), aggregates of capsid proteins devoid of viral genetic
material, show great promise in the fields of vaccine development and gene therapy. These …

Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer

K Tegerstedt, AV Franzén, K Andreasson… - Anticancer …, 2005 - ar.iiarjournals.org
This review describes the use of murine polyomavirus “virus-like” particles (MPyV-VLPs),
free from viral genes, as vectors for gene and immune therapy and as vaccines. For large …

[BOOK][B] Viral nanotechnology

Y Khudyakov, P Pumpens - 2015 - books.google.com
This book presents a review of a rapidly developing field of viral nanotechnology in the
context of immunology, virology, microbiology, chemistry, physics, and mathematical …

[HTML][HTML] Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells

A Gedvilaite, DC Dorn, K Sasnauskas, G Pecher… - Virology, 2006 - Elsevier
As polyomavirus major capsid protein VP1-derived virus-like particles (VLPs) have been
demonstrated to be highly immunogenic, we studied their interaction with human dendritic …

[HTML][HTML] Early transcriptome signatures from immunized mouse dendritic cells predict late vaccine-induced T-cell responses

N Dérian, B Bellier, HP Pham, E Tsitoura… - PLOS Computational …, 2016 - journals.plos.org
Systems biology offers promising approaches for identifying response-specific signatures to
vaccination and assessing their predictive value. Here, we designed a modelling strategy …

Murine polyomavirus tumour specific transplantation antigens and viral persistence in relation to the immune response, and tumour development

T Ramqvist, T Dalianis - Seminars in cancer biology, 2009 - Elsevier
Murine polyomavirus (MPyV) has been instrumental in the studies of transformation in vitro
as well as for in vivo studies of virus induced tumour development, and for the studies of …

Immunotherapy for polyomaviruses: opportunities and challenges

T Dalianis - Immunotherapy, 2012 - Future Medicine
Polyomaviruses are small DNA viruses present in mammals and birds, and in 1953 the first
one to be described was murine polyomavirus. It was not until 1971 that the first two human …

[BOOK][B] Medicinal protein engineering

YE Khudyakov - 2008 - taylorfrancis.com
An All-Inclusive Review of the Achievements and Trends in the Fast-Growing Protein
Engineering Field From humble beginnings like making fire for mere survival, engineering …

Comparison of Dendritic Cell Activation by Virus-Based Vaccine Delivery Vectors Emphasizes the Transcriptional Downregulation of the Oxidative Phosphorylation …

E Tsitoura, D Kazazi, D Oz-Arslan, EA Sever… - Human gene …, 2019 - liebertpub.com
Antigen delivery platforms based on engineered viruses or virus-like particles are currently
developed as vaccines against infectious diseases. As the interaction of vaccines with …

[PDF][PDF] 10 Polyomavirus-Derived Virus-Like Particles

RG Ulrich, A Gedvilaite, T Voronkova, A Kazaks… - Medicinal Protein …, 2009 - nzdr.ru
Initially, polyomaviruses had been grouped together with papillomaviruses into the family
Papovaviridae due to similarities of both virus groups regarding virion morphology and …